Literature DB >> 23817893

Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis.

M Dawn Teare1, Rachel Knevel, Michael D Morgan, Agnieszka Kleszcz, Paul Emery, David J Moore, Philip Conaghan, Tom W J Huizinga, Ann W Morgan, Annette H M van der Helm-van Mil, Anthony G Wilson.   

Abstract

OBJECTIVE: There is increasing evidence to indicate that genetic factors contribute significantly to radiologic joint damage in rheumatoid arthritis (RA). The aim of the present study was to determine whether genotypes of 10 recently identified RA susceptibility loci are associated with radiologic severity.
METHODS: A 2-stage study was performed using 3 Northern European RA populations: a British cross-sectional population (discovery cohort; n=885) and the Leiden Early Arthritis Clinic (EAC) cohort (n=581) and Yorkshire Early Arthritis Register (YEAR) cohort (n=418) (validation cohorts). Radiologic damage was assessed using a modified Larsen method for scoring radiographs (in the discovery cohort) or modified Sharp/van der Heijde score (in the 2 validation cohorts). A meta-analysis was performed to bring together the evidence from the 3 studies, using data on radiologic severity of joint damage from a single time point.
RESULTS: An allele-dose association of rs26232 was present in the discovery population (P=4×10(-4)); the median modified Larsen scores of radiologic joint damage per genotype were 31 (for those with CC), 27 (for those with CT), and 16 (for those with TT). The allele-dose association of rs26232 was replicated in both the Leiden EAC cohort during the initial 7 years of RA (P=0.04) and the YEAR cohort (P=0.039). In a fixed-effects meta-analysis of all 3 studies, the per T allele effect on the ratio of radiologic severity scores was 0.90 (95% confidence interval 0.84, 0.96; P=0.004).
CONCLUSION: The variant rs26232, in the first intron of the C5orf30 locus, is associated with the severity of radiologic damage in RA and is independent of established prognostic biomarkers. The biologic activities of C5orf30 are unknown, but our genetic data suggest that it is involved in mediating joint damage in RA.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817893     DOI: 10.1002/art.38064

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis.

Authors:  Munitta Muthana; Sarah Hawtree; Adam Wilshaw; Eimear Linehan; Hannah Roberts; Sachin Khetan; Gbadebo Adeleke; Fiona Wright; Mohammed Akil; Ursula Fearon; Douglas Veale; Barbara Ciani; Anthony G Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-27       Impact factor: 11.205

2.  Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis?

Authors:  Ian C Scott; Frühling Rijsdijk; Jemma Walker; Jelmar Quist; Sarah L Spain; Rachael Tan; Sophia Steer; Yukinori Okada; Soumya Raychaudhuri; Andrew P Cope; Cathryn M Lewis
Journal:  J Rheumatol       Date:  2015-05-15       Impact factor: 4.666

3.  Dense Genotyping of Immune-Related Regions Identifies Loci for Rheumatoid Arthritis Risk and Damage in African Americans.

Authors:  Maria I Danila; Vincent Albert Laufer; Richard J Reynolds; Qi Yan; Nianjun Liu; Peter K Gregersen; Annette Lee; Marlena Kern; Carl D Langefeld; Donna K Arnett; S Louis Bridges
Journal:  Mol Med       Date:  2017-06-29       Impact factor: 6.354

4.  IL2RA is associated with persistence of rheumatoid arthritis.

Authors:  H W van Steenbergen; J A B van Nies; A Ruyssen-Witrand; T W J Huizinga; Al Cantagrel; F Berenbaum; A H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2015-09-08       Impact factor: 5.156

5.  A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis.

Authors:  Hanna W van Steenbergen; Luis Rodríguez-Rodríguez; Ewa Berglin; Alexandra Zhernakova; Rachel Knevel; Jose Ivorra-Cortés; Tom W J Huizinga; Benjamin Fernández-Gutiérrez; Peter K Gregersen; Solbritt Rantapää-Dahlqvist; Annette H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2015-01-08       Impact factor: 5.156

Review 6.  Genetics of rheumatoid arthritis susceptibility, severity, and treatment response.

Authors:  Sebastien Viatte; Anne Barton
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

7.  Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases.

Authors:  Matthew Traylor; Rachel Knevel; Jing Cui; John Taylor; Westra Harm-Jan; Philip G Conaghan; Andrew P Cope; Charles Curtis; Paul Emery; Stephen Newhouse; Hamel Patel; Sophia Steer; Peter Gregersen; Nancy A Shadick; Michael E Weinblatt; Annette Van Der Helm-van Mil; Jennifer H Barrett; Ann W Morgan; Cathryn M Lewis; Ian C Scott
Journal:  PLoS One       Date:  2019-10-09       Impact factor: 3.240

8.  Regulation of gene expression in autoimmune disease loci and the genetic basis of proliferation in CD4+ effector memory T cells.

Authors:  Xinli Hu; Hyun Kim; Towfique Raj; Patrick J Brennan; Gosia Trynka; Nikola Teslovich; Kamil Slowikowski; Wei-Min Chen; Suna Onengut; Clare Baecher-Allan; Philip L De Jager; Stephen S Rich; Barbara E Stranger; Michael B Brenner; Soumya Raychaudhuri
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

9.  EM Adaptive LASSO-A Multilocus Modeling Strategy for Detecting SNPs Associated with Zero-inflated Count Phenotypes.

Authors:  Himel Mallick; Hemant K Tiwari
Journal:  Front Genet       Date:  2016-03-30       Impact factor: 4.599

10.  Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis.

Authors:  Sebastien Viatte; James C Lee; Bo Fu; Marion Espéli; Mark Lunt; Jack N E De Wolf; Lily Wheeler; John A Reynolds; Madhura Castelino; Deborah P M Symmons; Paul A Lyons; Anne Barton; Kenneth G C Smith
Journal:  Arthritis Rheumatol       Date:  2016-11       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.